Editor´s Pick

      Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

      NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (COMIRNATY 2023-2024 Formulation) for individuals 12 years and older and granted emergency use authorization for individuals 6 months through 11 years of age for the companies’ Omicron XBB.1.5-adapted monovalent COVID-19 vaccine. This season’s vaccine is indicated as a single do

      Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union

      NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies’ Omicron XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) administered as a single dose for individuals 5 years of age and older, regardless of prior COVID-19 vaccination history. The Committee has al

      Mahana Therapeutics Signs Agreement with Consumer Health Division of Bayer to Commercialize Digital Therapeutics

      SAN FRANCISCO & BASEL, Switzerland--(BUSINESS WIRE)-- #digitalhealth--Mahana Therapeutics, a leading provider of prescription digital therapeutics, announced today that the company has entered into a multi-million-dollar distribution and marketing partnership with the Consumer Health division of Bayer to commercialize digital therapeutics. Earlier this year, Bayer announced the launch of a new business unit focused on delivering new digitally enabled precision health products to market. Bayer is prioritizing de

      Meissa Vaccines Announces Positive Clinical Data for the First RSV Vaccine Designed to Protect Infants and Toddlers

      REDWOOD CITY, Calif.--(BUSINESS WIRE)-- #COVID19--Meissa Vaccines Announces Positive Clinical Data for the First RSV Vaccine Designed to Protect Infants and Toddlers

      Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy

      CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics announces the FDA approval of ELEVIDYS, the first gene therapy approved to treat Duchenne muscular dystrophy.

      Bayer Announces Senior Bayer Representative and President of Bayer U.S.

      WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, one of the country’s leading life-sciences companies, today announced its new Senior Bayer Representative and President of Bayer U.S. Sebastian Guth, Bayer’s President of Pharmaceuticals Americas, assumes this leadership role, which oversees all Bayer U.S. operations, on June 30, 2023. Guth, who has been with Bayer for 17 years, will retain leadership of the Pharmaceuticals business for the U.S., a critical growth market for the company, and Canada. Bayer

      Recent Articles